IN2013MN02443A - - Google Patents

Download PDF

Info

Publication number
IN2013MN02443A
IN2013MN02443A IN2443MUN2013A IN2013MN02443A IN 2013MN02443 A IN2013MN02443 A IN 2013MN02443A IN 2443MUN2013 A IN2443MUN2013 A IN 2443MUN2013A IN 2013MN02443 A IN2013MN02443 A IN 2013MN02443A
Authority
IN
India
Prior art keywords
pyrroloquinolinyl
pyrrole
dione
formulations
administering
Prior art date
Application number
Inventor
Hiroshi Yamakose
Takafumi Kato
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of IN2013MN02443A publication Critical patent/IN2013MN02443A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

The present invention provides pyrroloquinolinyl pyrrole 2 5 dione formulations and methods of treating a cell proliferative disorder such as a cancer by administering to a subject in need thereof a therapeutically effective amount of the formulations containing pyrroloquinolinyl pyrrole 2 5 dione compounds.
IN2443MUN2013 2011-07-07 2012-07-06 IN2013MN02443A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505175P 2011-07-07 2011-07-07
PCT/US2012/045688 WO2013006761A2 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same

Publications (1)

Publication Number Publication Date
IN2013MN02443A true IN2013MN02443A (en) 2015-06-12

Family

ID=47437711

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2443MUN2013 IN2013MN02443A (en) 2011-07-07 2012-07-06

Country Status (14)

Country Link
US (2) US9180099B2 (en)
EP (1) EP2729145A4 (en)
JP (1) JP6073310B2 (en)
KR (1) KR20140146036A (en)
CN (1) CN103930110A (en)
AU (1) AU2012278831A1 (en)
BR (1) BR112013033807A2 (en)
CA (1) CA2839584A1 (en)
IN (1) IN2013MN02443A (en)
MX (1) MX2014000253A (en)
PH (1) PH12015501980A1 (en)
TW (1) TW201315470A (en)
WO (1) WO2013006761A2 (en)
ZA (1) ZA201400108B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2547148C2 (en) * 2005-02-09 2015-04-10 Аркьюл, Инк. Compositions and methods of treating cancer
CN104379144A (en) 2012-04-23 2015-02-25 艾科尔公司 Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
PT1294358E (en) * 2000-06-28 2004-12-31 Smithkline Beecham Plc MOORING PROCESS BY HUMIDITY
JP4776229B2 (en) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド Stable nanoparticulate active substance liquid dosage composition
UA89513C2 (en) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
EP1849830B1 (en) * 2005-01-28 2012-02-29 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
RU2547148C2 (en) 2005-02-09 2015-04-10 Аркьюл, Инк. Compositions and methods of treating cancer
JP5044398B2 (en) * 2005-06-09 2012-10-10 武田薬品工業株式会社 Solid preparation
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
AU2007226983A1 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
TWI405590B (en) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd Method of producing pulverized organic compound particle
CN101474175B (en) * 2009-01-20 2014-07-02 重庆医药工业研究院有限责任公司 Oral solid preparation of Febuxostat with high-bioavailability and preparation method thereof
MX2011008584A (en) * 2009-02-12 2012-01-27 Kyowa Hakko Kirin Co Ltd A composition comprising (-) -trans-3- (5, 6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent.
NZ628087A (en) * 2009-12-23 2016-02-26 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Also Published As

Publication number Publication date
AU2012278831A1 (en) 2014-01-16
PH12015501980A1 (en) 2017-10-18
WO2013006761A2 (en) 2013-01-10
JP2014518284A (en) 2014-07-28
EP2729145A4 (en) 2014-12-10
US20160022667A1 (en) 2016-01-28
CN103930110A (en) 2014-07-16
MX2014000253A (en) 2014-10-17
EP2729145A2 (en) 2014-05-14
ZA201400108B (en) 2016-03-30
CA2839584A1 (en) 2013-01-10
US9180099B2 (en) 2015-11-10
WO2013006761A3 (en) 2013-04-18
TW201315470A (en) 2013-04-16
KR20140146036A (en) 2014-12-24
US20130011481A1 (en) 2013-01-10
JP6073310B2 (en) 2017-02-01
BR112013033807A2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
PH12018501410A1 (en) Therapeutically active compounds and their method of use
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MX350432B (en) Therapeutically active compounds and their methods of use.
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX2020010535A (en) Methods of treating cancer.
MX344530B (en) Substituted benzene compounds.
MX342951B (en) Therapeutically active compositions and their method of use.
PH12015500825B1 (en) Substituted benzene compounds
CR20200479A (en) Therapeutically active compounds and their methods of use
UA109464C2 (en) Spiro-oxindoles as mdm2 antagonists
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX346375B (en) Spiro-oxindole mdm2 antagonists.
MX2009013815A (en) Quinazolinone compounds and methods of use thereof.
IN2013MN02443A (en)
MX2014006990A (en) Treatment of type i and type ii diabetes.
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
MX2012007471A (en) Substituted pyrrolo-aminopyrimidine compounds.